Changing the Paradigm in HER2-Positive Early Breast Cancer

New data and broad indications for trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings.

Presenters:

Sara A. Hurvitz, MD, FACP
Professor of Medicine
Smith Family Endowed Chair in Women’s Health
Senior Vice President, Clinical Research Division
Fred Hutch Cancer Center
Head, Division of Hematology/Oncology, Department of Medicine
University of Washington School of Medicine
Seattle, Washington

Shanu Modi, MD
Section Head, HER2 Breast Program
Professor and Attending Member
Breast Medicine Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Link to full program: 
https://bit.ly/4z1Xb6a

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.